Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Janssen Biotech and Johnson & Johnson Innovation have formed a research partnership with The Icahn School of Medicine, Mount Sinai, to develop scientific understanding of inflammatory bowel disease (IBD) and discover next generation therapeutic solutions.
Subscribe to our email newsletter
Janssen Immunology Therapeutic scientists and The Icahn School of Medicine researchers will jointly work to investigate disease triggers, identify new opportunities for therapeutic interventions and create diagnostics to help precision medicine and predictive biomarkers.
The collaboration helps in bringing together the research and development capabilities of Janssen with an early-stage life science investment through the Johnson & Johnson Innovation center in Boston and Mount Sinai’s expertise in computational biology, and clinical and translational research in IBD.
The partnership aims at building a Molecular Interaction Network of Disease (MIND) in IBD to yield high confidence therapeutic hypotheses to be tested in vitro and in vivo.
The Mount Sinai Medical Center Academic Affairs executive vice president and the Icahn School of Medicine Anne and Joel Ehrenkranz dean Dr Dennis Charney said, "Research alliances such as these, managed by the team at Mount Sinai Innovation Partners, allow us to develop, patent, license, and translate laboratory breakthroughs into clinical applications."
The detailed terms of the agreement were not disclosed.